Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, scientists preserved cognition in mice without dulling the cancer-killing ...

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolio Omeros is eligible to receive 340 million US dollars in ...

From this core mechanism Fc engineering has evolved over time into the "engine" of therapeutic antibody development. It enables precise modulation of immune effector functions, optimization of ...

Australian pensions are working to create a platform to share information on criminal activity including cyber threats to help thwart potential attacks, the Australian Financial Review reported The ...

I Am Become Death is the Final main quest for the Enclave Faction in Appalachia, received from MODUS after earning enough military commendations in the quest Officer on Deck I am Become Death is your ...

Meet the boys of the Tangaroa College First XV and the coach that turned the team from a struggling side to 1A contenders. Video / Anthony Costello New Zealand still has plenty of schoolboy rugby ...

Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) is a rare disease that affects the filtering units in your kidneys (glomeruli). There are many types of glomerular diseases.